Ondansetrom Accord (Ondansetron)

Ondansetron is a selective 5‑HT3 receptor antagonist. It blocks serotonin receptors located on the vagus nerve and in the brain’s chemoreceptor trigger zone, preventing serotonin‑mediated activation of the vomiting centre and thereby reducing the sensation of nausea and the act of vomiting.

The dosage of Ondansetrom Accord is determined by the prescribing clinician based on the patient’s age, weight, the type of treatment (chemotherapy, radiation, or surgery), and clinical response. Healthcare providers set the appropriate dose and schedule for each individual case.

Safety data for ondansetron in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any potential risk to the fetus or infant. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss the risks and benefits with their healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and required import documentation.

Ondansetron belongs to the 5‑HT3 antagonist class, which is particularly effective for chemotherapy‑ and radiation‑induced nausea. Compared with dopamine antagonists (e.g., metoclopramide) or antihistamines, ondansetron provides more targeted control of serotonin‑mediated vomiting and generally has a lower incidence of extrapyramidal side effects.

Ondansetrom Accord should be stored at room temperature, below 25 °C. Keep the tablets in the original container, protect them from moisture and direct sunlight, and ensure the packaging remains tightly closed to maintain product stability.

Ondansetrom Accord is supplied as oral tablets that are taken by mouth with or without water. The exact timing relative to chemotherapy, radiation or surgery is determined by the prescribing clinician, who may advise administration before, during, or after the emetogenic stimulus.

Serious risks include QT interval prolongation, which can lead to potentially life‑threatening cardiac arrhythmias, and rare severe allergic reactions such as anaphylaxis. Patients should be monitored for signs of cardiac irregularities, especially if they are taking other QT‑prolonging drugs or have underlying heart disease.

Ondansetrom Accord should be avoided in individuals with known hypersensitivity to ondansetron or any other 5‑HT3 antagonists. Caution is also advised for patients with congenital long QT syndrome, significant cardiac disease, or those taking medications that strongly prolong the QT interval.